Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ticagrelor is an antiplatelet agent used for treatment of coronary artery disease via inhibition of the P2Y12 receptor.
|
31662237 |
2020 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
DAPT (aspirin and only clopidogrel among all P2Y12 inhibitors) might be maintained or initiated for CHD in patients with minor acute stroke and high-risk transient ischemic attack patient with IS attributable to an important intracranial stenosis, as long as this drug combination proved to be safe for them in the prevention of stroke recurrence.
|
30839370 |
2019 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ticagrelor, a P2Y12 receptor antagonist, is used in combination with aspirin in patients with coronary artery disease.
|
31482841 |
2019 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
P2Y12 receptor inhibitors are antiplatelet agents commonly prescribed in the treatment of coronary artery disease.
|
29580115 |
2018 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic windows for residual platelet reactivity in patients with coronary artery disease on P2Y12 inhibitors were proposed in a consensus document.
|
27609198 |
2017 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
P2Y12 receptor inhibitor resistance and coronary artery disease: a bench to bedside primer for cardiovascular specialists.
|
28661903 |
2017 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the correlations of three P2Y12 receptor (P2Y12R) gene polymorphisms (rs7428575 T>G, rs2046934 C>T, and rs3732759 A>G) with susceptibility to coronary artery disease (CHD) and clinical efficacy of clopidogrel treatment for CHD.
|
27566695 |
2016 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To investigate the genotype frequencies of cytochrome P450, family2, subfamily C, polypeptide19 (CYP2C19); P2Y12 receptor; and glycoprotein IIIa polymorphisms in patients with coronary heart disease and their impact on clopidogrel responsiveness and major adverse cardiac events (MACEs).A total of 146 coronary heart disease patients of Han ethnicity, on a clopidogrel regimen, were enrolled.
|
27488401 |
2016 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies showed that a blunted response to P2Y12 antagonist, that is, high on-treatment platelet reactivity (HTPR), is a strong predictor of major cardiovascular events (MACEs) in coronary heart disease (CHD) patients receiving antiplatelet treatment.
|
26221610 |
2015 |
Coronary heart disease
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Association of P2Y12 gene promoter DNA methylation with the risk of clopidogrel resistance in coronary artery disease patients.
|
24745016 |
2014 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prasugrel, a third-generation P2Y12 receptor antagonist, in patients with coronary artery disease undergoing elective percutaneous coronary intervention.
|
25342212 |
2014 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms.
|
22721490 |
2013 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
P2Y12 receptor is the major platelet receptor that mediates ADP-induced aggregation, P2Y12 receptor inhibitors such as clopidogrel and prasugrel inhibit platelet aggregation, and thus, they are used in the treatment and prevention of coronary artery disease.
|
23612493 |
2013 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
P2Y12 receptor gene polymorphism and antiplatelet effect of clopidogrel in patients with coronary artery disease after coronary stenting.
|
23751603 |
2013 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease.
|
22574824 |
2012 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel dose-adjustment according to platelet reactivity monitoring in coronary artery disease patients.
|
19914687 |
2010 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Common variation in the P2RY12 gene is a significant determinant of the interindividual variability in residual on-clopidogrel platelet reactivity in patients with coronary artery disease.
|
20031628 |
2009 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
We examined the association between 36 genotyped and 193 imputed SNPs within four lipid-lowering drug target genes (HMGCR, PPARA, HM74A/GPR109A and CETP) and four non-lipid drug target genes (ACE, AGTR1, P2RY12, and ATP4B) and lipid phenotypes, blood pressure, and coronary artery disease in 5635 adult participants of the Lausanne, Switzerland, CoLaus study, genotyped using the Affymetrix 500K SNP chip technology.
|
18787507 |
2008 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
P2Y12 polymorphisms and antiplatelet effects of aspirin in patients with coronary artery disease.
|
17995973 |
2008 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The H2 haplotype of the P2RY12 was determined in 1378 unrelated patients of both sexes selected according to the presence of significant coronary artery disease (CAD group) or having normal coronary angiogram at cardiac catheterization (CAD-free group).
|
17803810 |
2007 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We tested the described P2Y12 receptor haplotypes in a group of patients with coronary artery disease.
|
16405973 |
2006 |
Coronary heart disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene sequence variations of three platelet membrane receptors (GPIa/IIa, P2Y12, GPIIb/IIIa) pivotal to thrombus formation were assessed in 76 patients with coronary artery disease on chronic aspirin treatment.
|
17127487 |
2006 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.
|
16181985 |
2005 |
Coronary heart disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Carriage of P2Y12 H2 haplotype does not seem to affect the platelet response to a 600 mg loading dose of clopidogrel in coronary artery disease patients prior to stenting.
|
15795539 |
2005 |